Caption Management’s TG Therapeutics TGTX Stock Holding History

Caption Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-50,276	Closed	-$1.64M	–	2056
2025 Q3	$1.82M	Buy	+50,276	New	+$1.66M	0.01%	880
2023 Q4	–	Sell	-33,300	Closed	-$387K	–	1672
2023 Q3	$278K	Buy	+33,300	New	+$464K	﹤0.01%	1053
2023 Q2	–	Sell	-34,629	Closed	-$894K	–	1401
2023 Q1	$521K	Buy	+34,629	New	+$526K	0.01%	780
2022 Q4	–	Sell	-425,000	Closed	-$3.08M	–	1705
2022 Q3	$2.52M	Buy	425,000 +355,000	+507%	+$2.33M	0.03%	558
2022 Q2	$298K	Buy	+70,000	New	+$437K	﹤0.01%	1175
2022 Q1	–	Sell	-639,900	Closed	-$7.41M	–	1943
2021 Q4	$12.2M	Buy	639,900 +594,900	+1,322%	+$15.4M	0.14%	188
2021 Q3	$1.5M	Buy	45,000 +39,750	+757%	+$1.23M	0.02%	885
2021 Q2	$204K	Buy	+5,250	New	+$206K	﹤0.01%	1176
2020 Q3	–	Sell	-8,800	Closed	-$172K	–	1253
2020 Q2	$172K	Sell	8,800 -36,200	-80%	-$583K	0.01%	807
2020 Q1	$443K	Buy	+45,000	New	+$568K	0.03%	569
2018 Q4	–	Sell	-20,900	Closed	-$117K	–	618
2018 Q3	$117K	Buy	+20,900	New	+$239K	0.01%	474

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Caption Management's TGTX Position: Q4 2025 in Review

Caption Management sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 50,276 shares — an estimated $1.64M sold.

Caption Management first reported a position in TGTX in Q3 2018 and held it in 11 quarters. The position peaked at $12.2M in Q4 2021. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

Caption Management reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
Caption Management sold 50,276 TG Therapeutics shares in Q4 2025, an estimated $1.64M.
Caption Management first reported a position in TG Therapeutics in Q3 2018 and held it in 11 quarters.
Caption Management's TG Therapeutics position peaked at $12.2M in Q4 2021.
351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.